RxDoctor Payments DataLook up a doctor →

Jack Pinto, MD

Interventional Cardiology · Kildeer, ILNPI 1992714034

Payments from drug & device makers

$87,337in general payments, 2019–2025

Across 542 payments — averaging $161.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$77K
  • Medtronic$2K
  • Novartis$935
  • E.r. Squibb & Sons, L.L.C.$914
  • Boehringer Ingelheim$723
  • Amarin Pharma, Inc.$641
  • plus $6K from 34 others

What the payments were for

  • Consulting fees$3750%
  • Speaking & faculty fees$71,75082%
  • Travel & lodging$2,2283%
  • Food & beverage$12,77315%
  • Education$2110%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$87,337 in reported general payments places this provider in the 85th percentile of 303 interventional cardiology providers in Illinois.

See all interventional cardiology providers in Illinois

Medicare billing

Part B allowed, 2024
$577,186
Medicare patients
957
Services billed
5,634

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban410$528,383
EntrestoSacubitril/Valsartan208$335,409
JardianceEmpagliflozin169$236,655
Repatha SureclickEvolocumab140$168,785
XareltoRivaroxaban76$112,223
Repatha SyringeEvolocumab25$28,239
Praluent PenAlirocumab36$26,283
VascepaIcosapent Ethyl22$20,526
Ezetimibe515$13,763
Metoprolol Succinate721$13,156
Icosapent Ethyl16$8,306
Rosuvastatin Calcium715$8,009
Atorvastatin Calcium715$7,758
Ranolazine ErRanolazine39$6,636
ClopidogrelClopidogrel Bisulfate507$5,942

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$156$528,383410 claims
NovartisEntresto$935$335,409208 claims
Boehringer IngelheimJardiance$723$236,655169 claims
Johnson & JohnsonXarelto$634$112,22376 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 303 interventional cardiology providers in Illinois.

Other interventional cardiology in Kildeer

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →